PDE5 inhibitors could increase the effectiveness of existing HCC therapies by permitting additional immune cells into a tumor, thereby weakening the immune system's ability to suppress the tumor and restoring normal blood flow to the area surrounding the tumor. Here, PDE5A is linked to neoplasm.